Guidance, NICE advice and quality standards in development

Showing 351 to 360 of 385

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Total hip arthroplasty using the superpath approach for osteoarthritis	Interventional procedures guidance	TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]	Technology appraisal guidance	TBC
Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessment	Health technology evaluation	TBC
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	10 September 2025
Treatments for non-small-cell lung cancer [ID6234]	Technology appraisal guidance	TBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]	Technology appraisal guidance	24 July 2024
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]	Technology appraisal guidance	TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]	Technology appraisal guidance	25 September 2024